INTRODUCTION
Mineral and bone disorders (CKD-MBD) are common chronic kidney disease (CKD) complications associated with cardiovascular outcomes and mortality in dialysis patients [1–5]. The spectrum of bone disease in peritoneal dialysis (PD) patients is yet to be clarified; it has recently been shown that up to 54% of patients with parathormone (PTH) within the goal recommended by KDIGO [6] had histomorphometry compatible with low bone turnover (LBT), according to Pereira et al [7]. In this case, many abnormalities of calcium and phosphate metabolism are described, mainly the presence of a positive calcium balance, which may result in an over-suppression of PTH [8,9]. Moreover, without efficient phosphate binding therapy, all PD patients have a positive phosphorus balance, witnessing continuous intrinsic inflammation activity accompanied by calcium and phosphorus imbalance, leading to extraosseous calcifications (EC), especially vascular calcifications (VC), regardless of bone turnover [10]. As a result, a reduction in serum calcium, phosphate and parathyroid levels control are important to prevent EC, while a solution of sodium thiosulphate (STS) has been used to treat a variety of metastatic calcifications related to CKD-MBD, acting as a potent calcium chelator, antioxidant, and vasodilator agent. Herein, we report a case of a young female CKD patient on PD with adynamic bone disease (ABD) and brown tumour (BT), who was successfully treated by intravenous STS, which was the cornerstone treatment.